Use of Iron Therapy in Chronic Kidney Disease
Journal Title: Archives of Clinical Nephrology - Year 2016, Vol 2, Issue 1
Abstract
Anemia is a common complication in patients with chronic kidney disease (CKD), and increases with the progression of renal dysfunction [1]. The main cause of anemia is the inadequate production of erythropoietin (EPO), a glycoprotein mainly produced by the kidney responsible for the growth of erythroid cells in the bone marrow [2]. Iron deficiency is another common cause of anemia in these patients and is a major cause of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) [3]. Approximately, 50% of patients with CKD, who have anemia and are not receiving ESA or iron supplementation show depleted iron stores in their bone marrow [4]. Although the use of intravenous iron in hemodialysis patients has significantly increased during the last decade [5], the appropriate iron dosing strategy in CKD remains debatable.
Authors and Affiliations
Rottembourg Jacques, Rostoker Guy
Keywords
Related Articles
- EP ID EP344750
- DOI 10.17352/acn.000004
- Views 111
- Downloads 0
Illness Perception and Hopelessness in Hemodialysis
Background: Illness perception is useful in understanding the impact of hopelessness on ESRD patients. This perception has been found to be an important determinant of behavior and has been associated with a number of im...
Rapidly Progressive Glomerulonephritis Associated with Systemic Lupus Erythematosus
Lupus nephritis is a frequent manifestation of multisystem autoimmune disease - Systemic Lupus Erythematosus and a significant cause of both acute renal injury and the end stage renal disease. Renal involvement is observ...
Wunderlich syndrome; Spontaneous Atraumatic Rupture of the kidney: A case report
Atraumatic spontaneous retroperitoneal haemorrhage is a distinct clinical entity with potentially life-threatening complications. The commonest aetologies include ruptured aortic or visceral aneurysm, spontaneous rupture...
Echinocandins and Continuous Renal Replacement Therapies: The Role of Adsorption
The following reviews [1,2], about continuous renal replacement therapies (CRRT) and echinocandins conclude that the membranes do not significantly adsorb these antifungals.
Thrombotic Microangiopathy Caused by Gemcitabine in a Patient with Duodenal Cancer
Gemcitabine (2’,2’-difluorodeoxycytidine) is a potent pyrimidine antimetabolite and was introduced in 1987. It is commonly used for various tumors including non-small cell lung cancer, pancreatic cancer, breast cancer, o...